"NSCLC registrational trial progression continues. This new data continues to strengthen the
clinical case for advancement of Efti in NSCLC. Immutep continue to finalise registrational trial
design (Phase II/III) to evaluate Efti in combination with anti-PD-1 assets (including potential for a
triple chemotherapy combination) in a 1L setting. We are anticipating updates on the outcomes
of FDA discussions in the current current quarter, which will provide more clarity as to trial timelines, but
also financial requirements."
Part of the latest resaerch of Wilson.
"NSCLC registrational trial progression continues. This new data...
-
- There are more pages in this discussion • 1,178 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |